Valuation: AstraZeneca Pharma India Limited

Market Cap 157B 1.65B 1.48B 1.36B 1.23B 2.31B 2.35B 16.25B 6.52B 82.63B 6.21B 6.08B 261B P/E 2025
186x
P/E 2026 103x
Enterprise Value 154B 1.62B 1.45B 1.33B 1.21B 2.26B 2.3B 15.9B 6.38B 80.86B 6.08B 5.95B 255B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
19.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-1.32%
1 week+4.93%
Current month-1.32%
1 month+4.19%
3 months-22.46%
6 months-23.54%
Current year-30.26%
1 week 5,995
Extreme 5995
6,445.95
1 month 5,660
Extreme 5660
6,445.95
Current year 5,660
Extreme 5660
9,219.25
1 year 5,660
Extreme 5660
9,850
3 years 4,050.15
Extreme 4050.15
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Chief Tech/Sci/R&D Officer - 03/03/2025
Compliance Officer - 23/02/2026
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 53 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%+4.93%-34.11%+35.01% 1.68B
-0.60%+10.21%+57.24%+142.93% 1,263B
-1.69%+0.70%+43.97%+78.49% 658B
-2.04%+0.25%+35.62%+100.66% 521B
-1.62%0.00%+52.79%+66.49% 391B
-0.71%+5.41%+79.67%+44.10% 369B
-1.76%+3.11%+32.10%+55.26% 307B
-0.77%+7.67%+11.94%+33.56% 290B
-0.61%+4.00%+56.06%+73.45% 252B
-1.04%+5.77%+37.53%+106.64% 212B
Average -1.23%+5.94%+37.28%+73.66% 426.36B
Weighted average by Cap. -1.19%+6.60%+48.11%+92.56%

Financials

2025 2026
Net sales 17.16B 181M 162M 149M 135M 252M 257M 1.78B 713M 9.03B 678M 664M 28.47B 22.76B 240M 215M 197M 179M 334M 341M 2.35B 945M 11.97B 899M 880M 37.75B
Net income 1.16B 12.19M 10.92M 10.04M 9.1M 17.01M 17.33M 120M 48.07M 609M 45.75M 44.77M 1.92B 1.88B 19.75M 17.69M 16.27M 14.74M 27.56M 28.07M 194M 77.88M 986M 74.12M 72.54M 3.11B
Net Debt -5B -52.7M -47.2M -43.42M -39.34M -73.53M -74.91M -518M -208M -2.63B -198M -194M -8.3B -3.37B -35.5M -31.79M -29.24M -26.5M -49.53M -50.46M -349M -140M -1.77B -133M -130M -5.59B
Projected Income Statement - Annual - AstraZeneca Pharma India Limited
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
02/11/26 INR 6,283.25 -1.32% 396
30/10/26 INR 6,367.35 +1.10% 119
29/10/26 INR 6,298.05 +1.02% 410
28/10/26 INR 6,234.70 +2.66% 1,034
27/10/26 INR 6,073.10 -0.03% 120
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock